Investor Relations

TIDES USA 2023

Engineered enzymes for oligonucleotide synthesis

Latest Financial Results

Q1 2023

Quarter Ended Mar 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Codexis, Inc. (Nasdaq: CDXS)  is a leading enzyme engineering company that applies its technology to discover and develop novel, high performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of small molecule pharmaceuticals, in RNA and DNA synthesis and the creation of next generation life science tools, and as gene therapies and oral enzyme therapies. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved return on capital in manufacturing, improved sensitivity in genomic and diagnostic applications, and more efficacious therapeutics.

Stock Snapshot

IR Contacts

Headquarters

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
T: 650-421-8100
Lauren Musto
media@codexis.com

Investor Relations

Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
T: 650-421-8399
Carrie McKim
ir@codexis.com

Transfer Agent

EQ Shareowner Services
1110 Centre Pointe Curve
Suite 101
Mendota Heights, MN 55120-4100
T: 800-468-9716
https://www.shareowneronline.com